Diuretic dosing in acute decompensated heart failure: Lessons from DOSE

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 260-265

  Campbell, Patrick T ^a   Ryan, Jason ^b  

^a Ochsner Medical Center   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Continuous infusion; Diuretic; DOSE trial; Heart failure; Serum creatinine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PLACEBO; CREATININE; FUROSEMIDE;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIURESIS; DIURETIC THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT PLANNING; ACUTE DISEASE; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MIDDLE AGED; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 84871855495     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0094-8     Document Type: Article

References (41)

1. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-479.
2. BrestAN, Seller R, Onesti G, et al. Clinical selection of diuretic drugs in management of cardiac edema. Am J Card. 2004;22:168-76.
3. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;6:475-528.
4. Emerman CL, Marco TD, Constanzo MR, et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE (R) Registry. J Card Fail. 2004;10:S116-7.
5. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364 (9):797-805.
6. Sica DA. Edema mechanisms in the patient with heart failure and treatment options. Heart Failure Clinics. 2008;4:511-8.
7. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-85. (Pubitemid 29384167)
8. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Jan 5. This is a comprehensive review of the pathophysiology of heart failure with focus on the neuroendocrine system, pressure-volume relationships, and ventricular remodeling.
9. Franics GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Int Med. 1985;103:1-6. (Pubitemid 15068490)
10. Francis GS, Benedict C, Johnstone DE, Kirlin PC, et al. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive heart failure - A substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-9. (Pubitemid 20367975)
11. Bayliss J, Norell M, Canepaanson R, Sutton G, et al. Untreated heart failure - clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22. (Pubitemid 17216948)
12. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44:1301-7. (Pubitemid 39208889)
13. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. On behalf of the membership advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83:1A-38A.
14. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293-302.
15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
16. Godwin TF, Gunton RW. Clinical trial of a new diuretic, furosemide: comparison with hydrochlorothiazide and mercaptomerin. Canadian Medical Association Journal. 1965;93(25):1296-300.
17. Dube P, Weber KT. Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part 1. Am J Med Sci. 2011;342(5):348-51.
18. Leary WP, Reyes AJ. Diuretic-induced magnesium losses. Drugs. 1984;29 suppl 1:182-7. (Pubitemid 14012578)
19. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with Thiazide-type diuretics in Heart Failure. J Am Coll Cardiol. 2010;56:1527-34. This state-of-the-Art paper reviews the current data regarding combination diuretic therapy in refractory or diuretic-resistant heart failure, highlighting the need for largescale clinical trials to develop safe and effective treatment strategies for advanced heart failure. The paper reviews the physiology and pathophysiology of diuretics in heart failure.
20. Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005;19:301-6. (Pubitemid 41778811)
21. Klein L, O'Conner CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIMIZE-HF) study. Circulation. 2005;111:2454-60. (Pubitemid 40696133)
22. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-5. (Pubitemid 29440124)
23. Sica DA, Gehr TW. Diuretic combinations in refractory edema states: pharmacokinetics/pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229-49.
24. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physio. 2003;284:F11-21. (Pubitemid 35471281)
25. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, et al. BG9719 (CVT-124), an A(1) adenosine receptor antagonist, protects against decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-53. (Pubitemid 34260427)
26. Liguori A, Casini A, Di Loreto M, et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons and in patients with chronic heart failure. Eur J Clin Pharmacol. 1999;55:117-24. (Pubitemid 29196264)
27. Sjostrom PA, Kron BG, Odlind BG. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration. Eur J Clin Pharmacol. 1993;45:135-9. (Pubitemid 23267416)
28. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and developing worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-8. (Pubitemid 38176835)
29. Hasselblad V, Stough WG, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPR trial. Eur J Heart Fail. 2007;9:1064-9. (Pubitemid 47451811)
30. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-64. (Pubitemid 43817867)
31. Philbin EF, Cotto M, Rocco Jr. TA, Jenkins PL. Association between diuretic use, clinical response and death in acute heart failure. Am J Cardiol. 1997;80:519-22. (Pubitemid 27371765)
32. Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388-93. (Pubitemid 351749839)
33. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450-8. (Pubitemid 13009620)
34. Kaissling B, Bachman S, KrizW. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol. 1985;248:F374-381. (Pubitemid 15142307)
35. Dormans TPJ, van Meyel JJM, Gerlag PGG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. Journal of the American College of Cardiology. 1996;28:376-82. (Pubitemid 26274331)
36. Licata G, Di Pasquale P, Parrinello G, et al. Effects of high doses of furosemide and small volume hypertonic saline solution infusion in comparison with high dose of furosemide as a bolus in refractory congestive heart failure. American heart Journal. 2003;145:459-66. (Pubitemid 36390492)
37. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous Infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005 Jul 20;(3): CD003178.
38. Aaser E, Gullestad L, Tollofsrud S, Lundberg J, et al. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neruohormonal activation in patients with severe congestive heart failure. Scandinavian Journal of Clinical and Laboratory Investigation. 1997;57:361-8.
39. Krammer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. Journal of Clinical Pharmacology. 1996;36:265-70. (Pubitemid 26117027)
40. Allen LA, Turer AT, DeWald T et al. Continuous versus Bolus Dosing of Furosemide for Patients Hospitalized for Heart Failure. Am J Cardiol 2010;105:1794-1797. This paper presents the data from a prospective, open-label, single-center, randomized trial evaluating bolus injection versus continuous infusion of furosemide in acute decompensated heart failure. The study enrolled 41 patients with a mean EF of 35%. The authors found no difference in regards to change in serum creatinine, urine output, electrolyte abnormalities, or length of stay between the two treatment strategies. The authors concluded that continuous infusion and bolus dosing of furosemide were of equal effectiveness and safety in acute decompensated heart failure.
41. Thompson MR, Nappi JM, Dunn SP et al. Continuous versus Intermittent Infusion of Furosemide in Acute Decompensated Heart Failure. J Cardiac Fail. 2010;16:188-193. This small (56 patient), prospective, randomized parallel study evaluated the effectiveness of continuous and intermittent infusion of intravenous diuretics. Patients receiving continuous infusion furosemide experienced significantly greater diuresis compared to intermittent infusion (3726±1121 mL/24 h vs 2955±1267 mL/24 h, respectively [P00.019]). The authors concluded that continuous infusion was safe and more effective than intermittent infusion.